Madrigal Q2 2025: Rezdiffra sales $212.8M, 23k patients; new patent to 2045; $500M credit

MADRIGAL PHARMACEUTICALS, INC.

2025-Q2 EPS reported -$5.22 revenue$350,052,000

Q2 2025 Rezdiffra net sales $212.8M (vs $14.6M prior year); >23,000 patients on therapy as of June 30, 2025.
New U.S. patent (No. 12,377,104) covers Rezdiffra weight-threshold dosing; expires Feb 4, 2045 (previously Sept 30, 2044).
Licensed global rights to oral GLP-1 candidate SYH2086 from CSPC Pharma; enters clinic H1 2026 for MASH combination.
Secured $500M senior secured credit facility with Blue Owl: $350M initial term loan, $150M delayed draw, plus up to $250M incremental.
Positive CHMP opinion for Rezdiffra in Europe; EC decision expected Aug 2025; would be first MASH therapy in EU.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.